Oryzon will launch its first product onto the market
The outcome of the clinical trial for GynEC®-DX, Oryzon’s first product, has been presented this week at the 17th Biennial Meeting of the European Society for Gynaecological Oncology (ESGO) held in Milano (Italy).
GynEC®-DX, is a new diagnostic test for the early detection of endometrial cancer developed jointly with Reig Jofré Laboratories and expected to be launched on the Spanish market by 1Q-2012. According to the conclusions of this multi-centric double blind prospective clinical trial conducted in 16 Spanish hospitals under the supervision of Dr. Jordi Ponce, at Bellvitge Hospital, and Dr. Antonio Gil, at the Vall d’Hebron Universitary Hospital in Barcelona, GynEC®-DX allows to rule out the presence of tumour in 97% of cases through a sample of uterine aspirate, thus allowing a better assessment of whether further analysis, as i.e. histeroscòpies, are indicated.